Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
The future of spinal fusions is right here
Easing the burden of spine-related pain
Spine-related pain is taking a huge toll on our society: more days in bed, more days off work, and at a greater financial cost to westernized healthcare than any other condition. In fact, today, nearly 1 in 5 spinal fusion surgeries result in a non-union of the bones in the spine.
Here at Kuros Biosciences, we’re on a mission to ease this burden through superior biologics for better spinal fusions. And here’s how.
Superior spinal fusions
for today, and tomorrow
MagnetOs is a bone graft like no other. It grows bone even in soft tissue thanks to our unique NeedleGrip™ surface technology – for more efficient and predictable fusions.*†‡1-3
Fibrin-PTH is the latest innovation in our pipeline. The first ever investigational drug-biologic candidate to be evaluated for spinal fusion, it has the potential to be a true game changer.§
A word from our CEO, Joost de Bruijn
We are a Swiss-headquartered global innovation company with 150 years’ combined research experience in the field of biologics for spinal fusion. Our commercial & research footprint spans three continents and covers more than 10 markets.
Project Fusion: where Science & Clinical Evidence meet
We believe that a greater quality and quantity of science holds the key to easing the burden of spine surgery – especially as high non-union rates force surgeons, medical organizations and insurers to reassess the bone grafts they choose. Our response? Project Fusion: a global research program that brings together an unprecedented blend of scientific, pre-clinical and clinical studies.
Strategic Advisory Board
Our work is supported by some of the world’s pre-eminent spinal surgeons and experts.
Alpesh A. Patel, MD is the Director of Orthopedic Spine Surgery at Northwestern and a spine surgeon with fellowship training in both Orthopedic Spine Surgery and Neurosurgery. Dr. Patel specializes in cervical spine surgery and minimally invasive spine surgery.
Dr Alpesh A. Patel, MD, FACS
Director of Orthopedic Spine Surgery, Northwestern Medicine, Chicago, IL
Andrew Sama, MD is Co-Chief of HSS Spine where he specializes in the management of all traumatic, degenerative, and deformity-related conditions of the cervical, thoracic, and lumbosacral spine. Dr. Sama also serves as an Associate Professor of Clinical Surgery, Weill Medical College of Cornell University.
Dr Andrew A. Sama, MD
Co-Chief of HSS Spine, New York, NY
Kornelis Poelstra is board certified in orthopedic spine surgery. He specializes primarily in long-construct minimally invasive spine surgeries, adult spinal deformity, oncologic conditions, spinal fracture treatment and cervical disc replacements. He is one of the world leaders in Robotic Spine Surgery.
Dr Kornelis Poelstra, MD, PhD
The Robotic Spine Institute of Las Vegas - Nevada Spine Clinic, Las Vegas, NV
W.R. Walsh, PhD is a Professor in the Prince of Wales Clinical School, Division of Surgery at University of New South Wales in Sydney, Australia, and Director of Surgical & Orthopaedic Research Laboratories, Prince of Wales Hospital. His research lies at the interface between implanted materials and the connective tissues of the body.
Prof. Bill Walsh PhD
Professor, Division of Surgery at University of New South Wales, Sydney, Australia
Faheem Sandhu, MD, PhD, is Director of Spine Surgery at MedStar Georgetown University Hospital and Professor of Neurological Surgery at Georgetown University Medical Center. He specializes in minimally invasive and complex spinal surgery.
Dr Faheem Sandhu, MD, PhD
Director of Spine Surgery, MedStar Georgetown University Hospital, Chevy Case, MD
Richard (Todd) Allen, MD, is board-certified orthopedic surgeon with expertise in complex adult reconstruction procedures for deformity/scoliosis and tumors. He also specializes in complex disorders of the upper cervical spine and in degenerative, traumatic, and post-traumatic conditions.
Dr R. Todd Allen, MD, PhD
Associate Professor of Orthopaedic Surgery, UC San Diego Health, San Diego, CA
Find out more
about Kuros
For further information send us your details and we will be in touch.
Suggested Reading
References And Disclaimers
Find the latest data on posterolateral spine fusion rates for each category of bone graft on Pubmed.gov
MoreDiscover more of our research for MagnetOs bone graft on Pubmed.gov
MoreSee selected articles for parathyroid hormone (PTH) on Pubmed.gov
MoreSee our clinical research for MagnetOs and Fibrin-PTH on Clinicaltrials.gov
More1. Van Dijk, et al. eCM. 2021;41:756-73
2. Duan, et al. eCM. 2019;37:60-73.
3. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
*Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kuros.18a.co.
†MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
‡MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
§Fibrin-PTH (KUR-113) is an investigational drug-biologic combination product candidate. Fibrin-PTH (KUR-113) has been evaluated in animals for use in lumbar interbody fusion. The safety & efficacy of Fibrin-PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.
PROMO/KUR/GL/062-21/R00